Tenax Therapeutics filings document a Phase 3, development-stage pharmaceutical company developing cardiopulmonary therapies, including TNX-103 (oral levosimendan) for PH-HFpEF. Recent 8-K reports record financial results, clinical program updates for LEVEL and LEVEL-2, intellectual-property notices, and amendments to levosimendan license rights, including expanded worldwide rights for orally administered products.
Proxy and current-report filings also describe Nasdaq-listed common stock, executive appointments, employment and compensation arrangements, equity awards, governance matters, and named-executive pay disclosures. These records frame the company's capital structure, leadership responsibilities, material agreements, and clinical-stage operations around levosimendan development and commercialization rights.
Tenax Therapeutics, Inc. reports that Logos Global Management and related reporting persons jointly disclose beneficial ownership of 800,000 shares of Common Stock, representing 3.0% of the class based on 26,525,159 shares outstanding as of May 8, 2026. The filing states shared voting and dispositive power for the 800,000 shares and is signed by William Arsani on behalf of the reporting persons on 05/15/2026.
Tenax Therapeutics reported a Schedule 13G/A showing Stonepine entities and Jon M. Plexico jointly hold 975,200 shares of Common Stock, representing 3.7% of the class. The filing states the percentage is calculated based on 26,525,159 shares outstanding as of May 8, 2026.
The reporting persons disclose shared voting and dispositive power over the 975,200 shares and disclaim sole voting or dispositive power. The statement is signed by Jon M. Plexico on behalf of the reporting persons.
Tenax Therapeutics ownership update: a group of related Venrock entities and two individuals report aggregate beneficial ownership equal to 9.99% of Tenax Therapeutics common stock as of March 31, 2026, reflecting a contractual "Beneficial Ownership Blocker." The group reports shared beneficial ownership of 1,955,105 shares, and the filing cites 17,197,613 shares outstanding as of March 6, 2026 as the base for the percentage calculation. The filing lists component holdings, including 1,382,092 shares held by Venrock Healthcare Capital Partners EG, L.P., and describes warrants and pre-funded warrants subject to the blocker that limit further exercises above the stated ownership cap.
Tenax Therapeutics filing amended Schedule 13G/A reporting that Point72-affiliated persons beneficially own 533,965 shares of common stock, representing 3.1% of the class as of the close of business on March 31, 2026. The holdings are reported for Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen.
The filing states the shares are held by an investment fund managed by Point72 Asset Management; the reporting persons assert shared voting and dispositive power over the 533,965 shares. Signature block shows authorization by Jason M. Colombo dated 05/15/2026.
TENAX THERAPEUTICS, INC. amendment reports that Lind Global Fund II LP, Lind Global Partners II LLC and Jeff Easton each disclose ownership tied to 202,480 warrants to purchase common stock. The filing states those Warrants represent 0.78% of the class and contain a 9.9% beneficial ownership cap.
The Reporting Persons list a principal business address of 444 Madison Ave, Floor 41, New York, NY 10022 and the issuer address as 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517. Signatures are dated 05/15/2026.
TENAX THERAPEUTICS, INC. ownership update: a group of related investment entities led by Biotechnology Value Fund and affiliated entities reported aggregate derivative and equity holdings and the limits that constrain exercise rights. As of March 31, 2026, the Reporting Persons held Pre-Funded Warrants exercisable for an aggregate of 9,407,095 shares and Warrants for 4,851,812 shares; exercise blockers limit immediate conversion to 1,569,173 shares for the Reporting Persons. Based on the filing’s denominator (including outstanding shares and certain issuable shares), individual reported beneficial ownership percentages range from 0% to approximately 9.99% for affiliated entities and individuals.
Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report beneficial ownership of 1,447,782 shares of Tenax Therapeutics common stock. The holdings represent 5.5% of the class based on 26,525,159 shares outstanding as of May 8, 2026, per the issuer's Form 10-Q filed May 12, 2026.
The Master Fund directly holds the shares; Perceptive Advisors serves as the Master Fund's investment manager and Mr. Edelman is the managing member of Perceptive Advisors, each of whom may be deemed to beneficially own the same block. Shared voting and dispositive power are reported for the full block.
TENAX THERAPEUTICS, INC. reports beneficial ownership disclosures by Dellora Investments Master Fund LP, Dellora Investments LP and Kevin Pyun under an amended Schedule 13G/A. The filing lists 345,257 shares held by Dellora Investments Master Fund LP and 394,665 shares held by Dellora Investments LP and Mr. Pyun, representing 2.0% and 2.3% of the class, respectively, based on 17,197,613 shares outstanding as of March 6, 2026.
The filing notes shared voting and dispositive power for the reported holdings and includes an express disclaimer of beneficial ownership by Dellora Investments LP and Mr. Pyun pursuant to Rule 13d-4.
Tenax Therapeutics, Inc. amendment to a Schedule 13G/A reports that RTW Investments, LP and Roderick Wong beneficially own 1,867,630 shares of Common Stock, representing 9.99% of the class.
The filing states this percentage assumes exercise of 1,497,384 warrants held by the Reporting Persons and is calculated using 17,197,613 shares outstanding as of March 6, 2026. The warrants cannot be exercised to the extent doing so would cause ownership to exceed 9.99%.
Tenax Therapeutics reported a Form 4 showing its Chief Financial Officer, Thomas R. Staab II, receiving new equity compensation. He was granted 10,000 shares of common stock as a restricted stock award and 450,000 stock options with an exercise price of $11.95 per share.
The restricted stock vests 25% ten days after the grant date of May 11, 2026, with the remaining 75% vesting in three equal installments on the four-month, eight-month and twelve-month anniversaries, contingent on continued employment. The options expire on May 11, 2036 and vest 25% on May 11, 2027, with the balance vesting in substantially equal monthly installments over the following 36 months, also subject to continued employment.